CJ HealthCare acquires approval of new antiemetic ‘Akynzeo’

CJ HealthCare announced on the 1^st that a new antiemetic ‘Akynzeo Cap’ was approved by the Ministry of Food and Drug Safety.

With the Akynzeo’s approval, CJ HealthCare has firmed its position in the anticancer supplement market with Aloxi.

Akynzeo is a new drug containing ‘Palonosetron’ with ‘Netupitant’; Palonosetron is a 5-HT3 receptor antagonist known as a antiemetic, and ‘Netupitant’ is a...